Search - tctmd.com

Displaying 1 - 20 of 24

Sort: Relevancy | Date

News Daily News

Nearly 150 Million US Adults Eligible for CKM Syndrome Meds

Caitlin E. Cox

February 02, 2026

News Daily News

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

L.A. McKeown

January 31, 2025

News Opinion CV Team Dispatch

January 2025 Dispatch for the CV Team

L.A. McKeown

January 24, 2025

News Daily News

Misleading Statements Common in Online Ads for Compounded GLP-1s

L.A. McKeown

January 20, 2025

News Features

Weight-Loss Showdown: Is It Time for an RCT of Bariatric Surgery vs GLP-1s?

Michael O'Riordan

January 17, 2025

News Daily News

Tirzepatide Gets FDA Approval for Sleep Apnea in Adults With Obesity

L.A. McKeown

December 23, 2024

News Daily News

FDA Grants MACE Reduction Indication for Semaglutide

Todd Neale

March 08, 2024

News Daily News

Top General Cardiology and CVD Prevention News of 2023

Yael L. Maxwell

January 03, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for December 2023

Caitlin E. Cox

December 28, 2023

News Conference News AHA 2023

Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics

Todd Neale

November 11, 2023

News Daily News

FDA Grants Tirzepatide a New Indication for Obesity Management

L.A. McKeown

November 08, 2023

News Daily News

European Regulators Investigating CV Safety of Weight-Loss Drug Mysimba

Michael O'Riordan

September 15, 2023

News Daily News

EMA Investigating Suicidal Thinking With GLP-1 Drugs for Weight Loss

Michael O'Riordan

July 12, 2023

News Features

Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar

L.A. McKeown

May 12, 2023

News Daily News

Semaglutide Effective for Weight Loss in Adolescents: STEP TEENS

Michael O'Riordan

December 30, 2022

News Daily News

SURMOUNT-1: Tirzepatide Drastically Reduces Weight in Obese Patients

L.A. McKeown

June 09, 2022

News Daily News

FDA: Obesity Drug Lorcaserin Exits US Market Over Cancer Concerns

Shelley Wood

February 14, 2020

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2019

Caitlin E. Cox

January 31, 2019

News Daily News

Go With NOACs Over Warfarin in Most Cases: Updated A-fib Guidelines

Todd Neale

January 29, 2019

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

Advertisement

Nearly 150 Million US Adults Eligible for CKM Syndrome Meds

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

January 2025 Dispatch for the CV Team

Misleading Statements Common in Online Ads for Compounded GLP-1s

Weight-Loss Showdown: Is It Time for an RCT of Bariatric Surgery vs GLP-1s?

Tirzepatide Gets FDA Approval for Sleep Apnea in Adults With Obesity

FDA Grants MACE Reduction Indication for Semaglutide

Top General Cardiology and CVD Prevention News of 2023

TCTMD’s Top 10 Most Popular Stories for December 2023

Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics

FDA Grants Tirzepatide a New Indication for Obesity Management

European Regulators Investigating CV Safety of Weight-Loss Drug Mysimba

EMA Investigating Suicidal Thinking With GLP-1 Drugs for Weight Loss

Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar

Semaglutide Effective for Weight Loss in Adolescents: STEP TEENS

SURMOUNT-1: Tirzepatide Drastically Reduces Weight in Obese Patients

FDA: Obesity Drug Lorcaserin Exits US Market Over Cancer Concerns

TCTMD’s Top 10 Most Popular Stories for January 2019

Go With NOACs Over Warfarin in Most Cases: Updated A-fib Guidelines

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content